Marye B. S.
- Country
- The Netherlands
- Department
- Medical oncology
Research Overview
- Adjuvant Pembrolizumab Versus Placebo in High-Risk Stage III Melanoma Post-Resection: A Randomized, Double-Blind Phase 3 EORTC Trial
- Phase 3 Multicenter Trial of Neoadjuvant Ipilimumab and Nivolumab Versus Adjuvant Nivolumab in Patients with Macroscopic Stage III Melanoma
- Evaluation of Early Discontinuation of Nivolumab in Patients with Unresectable Stage III or Metastatic Melanoma Treated with First-Line Ipilimumab-Nivolumab Therapy
Data & Insights
Has run more than one trial at 32 of 83 partner sites.
Specializations
Melanoma Treatment Expertise
This investigator specializes in advanced therapeutic approaches for melanoma, with particular emphasis on stage III melanoma and metastatic melanoma management.
- Advanced and Metastatic Disease Treatment
- Stage III Melanoma Management
- Post-operative Adjuvant Therapy
Their research encompasses treatment optimization for both resectable and unresectable melanoma cases.
Immunotherapy Applications
The investigator focuses on innovative applications of immunotherapy treatments, particularly utilizing PD-1 inhibitors and combination therapeutic approaches.
- Monoclonal Antibody Therapy
- Combination Immunotherapy Protocols
- Treatment Response Assessment
Their work includes evaluation of novel immunotherapy discontinuation strategies and response monitoring.
Treatment Optimization
The investigator explores neoadjuvant and adjuvant therapy protocols, focusing on treatment timing and duration optimization.
- Response-guided Treatment Protocols
- High-risk Patient Management
- Long-term Outcome Assessment
Their research includes evaluation of treatment discontinuation strategies in responding patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.